[caption id="attachment_73307" align="aligncenter" width="500"]
Photo courtesy of Pexels[/caption]
If you’ve ever looked up weight loss tips, you’ve probably seen a mix of advice that sounds convincing but doesn’t always hold up in real life. Just like you might check a healthy Costco snacks guide to make smarter choices, it’s just as important to filter out myths that can slow down your progress. Let’s break down some of the most common ones and what actually works instead.
Let's break down some of the most common weight loss myths — and what actually works instead.
Photo courtesy of Pexels[/caption]
If you’ve ever looked up weight loss tips, you’ve probably seen a mix of advice that sounds convincing but doesn’t always hold up in real life. Just like you might check a healthy Costco snacks guide to make smarter choices, it’s just as important to filter out myths that can slow down your progress. Let’s break down some of the most common ones and what actually works instead.
Let's break down some of the most common weight loss myths — and what actually works instead.
Dr. Serena Guo[/caption]
Serena Jingchuan Guo, MD PhD
Assistant Professor
Department of Pharmaceutical Outcomes and Policy
University of Florida College of Pharmacy
[caption id="attachment_71231" align="alignleft" width="125"]
Dr. Hao Dai[/caption]
Hao Dai, PhD
Postdoctoral Fellow
Department of Biostatistics & Health Data Science
Indiana University School of Medicine
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Obesity and type 2 diabetes are both known to increase the risk of several cancers. Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have become very popular for both glycemic control and weight loss, but their long-term effects on cancer risk are still unclear. Using a large real-world dataset, we emulated a target trial comparing more than 43,000 GLP-1RA users to matched non-users.
We found that GLP-1RA use was associated with a significantly lower overall cancer risk.
Dr. Donofry[/caption]
Shannon D. Donofry Ph.D.
Behavioral Scientist
B.A.Sc. in psychology/neuroscience
University of Pittsburgh-Pittsburgh Campus;
Ph.D, University of Pittsburgh-Pittsburgh Campus
[caption id="attachment_70207" align="alignleft" width="125"]
Dr. Rancaño[/caption]
Katherine M. Rancaño, Ph.D
Associate Policy Researcher
RAND
MedicalResearch.com: What is the background for this study?
Response: GLP-1 medications were first used to help people with diabetes manage their blood sugar. Lately, they’ve become popular for helping people lose weight, too. Because of this, a lot more people have started using them. In our study, we asked over 8,000 adults from across the country about their use of GLP-1 medications and any side effects they had.
Prof. El GHOCH[/caption]
MedicalResearch.com Interview with:
Prof. Marwan EL GHOCH